Rituximab, ofatumumab and other monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemia

Cochrane Database of Systematic Reviews

Volumn 2017, Issue 12, 2012, Pages

  Bauer, Kathrin ^a   Rancea, Michaela ^a   Roloff, Verena ^b   Elter, Thomas ^a   Hallek, Michael ^a   Engert, Andreas ^a   Skoetz, Nicole ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b MRC BIOSTATISTICS UNIT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CD20 ANTIBODY; FLUDARABINE; MONOCLONAL ANTIBODY; OBINUTUZUMAB; OFATUMUMAB; RITUXIMAB; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; VIDARABINE;

CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; DISEASE ASSESSMENT; DRUG RESPONSE; EVIDENCE BASED PRACTICE; FOLLOW UP; HUMAN; META ANALYSIS; MORTALITY RATE; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VIDARABINE;

EID: 84873193703     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD008079.pub2     Document Type: Review

References (149)

1. Byrd JC, Gribben JG, Peterson BL, Grever MR, Lozanski G, Lucas DM, et al. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy. Journal of Clinical Oncology 2006;24:437-43.
2. Byrd JC, Peterson B, Park K, Morrison V, Vardiman JW, Jacobson RJ, et al. Rituximab added to fludarabine improves response in previously untreated chronic lymphocytic leukemia: preliminary results from CALGB 9712. Journal of Clinical Oncology 2001;20 (Pt 1):280a.
3. Byrd JC, Peterson BL, Morrison VA, Park K, Jacobson R, Hoke E, et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 2003;101(1):6-14.
4. Byrd JC, Peterson BL, Park K. Concurrent rituximab and fludarabine has a higher complete response rate than sequential treatment in untreated chronic lymphocytic leukemia (CLL) patients: results from CALGB 9712. Blood 2001;98(1):A-3212.
5. Byrd JC, Rai K, Peterson BL, Appelbaum FR, Morrison VA, Kolitz JE, et al. The addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 2005;105:49-53.
6. Morrison VA, Byrd JC, Peterson BL, Rai KR, Larson RA. Adding rituximab to fludarabine therapy for patients with untreated chronic lymphocytic leukemia (CLL) does not increase the risk of infection: Cancer and Leukemia Group B (CALGB) Study 9712. Blood 2003;102:440a.
7. Morrison VA, Peterson BL, Rai KR, Byrd JC, Larson JC. Alemtuzumab increases serious infections in patients with previously untreated chronic lymphocytic leukemia (CLL) receiving fludarabine-based therapy: a comparative analysis of 3 Cancer and Leukemia Group B studies (CALGB 9011, 9712, 19901). Blood 2007;110(11):A-756.
8. Woyach JA, Ruppert AS, Heerema NA, Peterson B, Gribben JG, Morrison VA, et al. Treatment with fludarabine and rituximab produces extended overall survival (OS) and progression-free survival (PFS) in chronic lymphocytic leukemia (CLL) without increased risk of second malignancy: long-term follow up of CALGB Study 9712. Blood 2009;114:539.
9. Woyach JA, Ruppert AS, Heerema NA, Peterson BL, Gribben JG, Morrison VA. Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712. Journal of Clinical Oncology 2011;29:1349-55.
10. Lepretre S, Aurran T, Mahe B, Cazin B, Tournihlac O, Maisonneuve H, et al. Immunochemotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) versus fludarabine (F), cyclophosphamide (C) and MabCampath (Cam) (FCCam) in previously untreated patients (pts) with advanced B-chronic lymphocytic leukemia (B-CLL): experience on safety and efficacy within a randomised multicenter phase III trial of the French Cooperative Group on CLL and WM (FCGCLL/MW) and the "Groupe Ouest-Est d'Etudes Des Leucemies Aigues Et Autres Maladies Du Sang" (GOELAMS): CLL2007FMP (for fit medically patients). Blood 2009;114:538.
11. Letestu R, Leprêtre S, Arnoulet C, Baseggio L, Campos L, Chatelain B, et al. Interest of early determination of bone marrow MRD by a sensitive 6-color flow cytometry in the evaluation of response: the experience of the CLL2007FMP, an intergroup phase III randomized multicentric trial comparing fludarabine cyclophosphamide (FC) and rituximab (FCR) versus FC and MabCampath (FCCam) in previously untreated B-chronic lymphocytic leukemia patients. Blood 2011;118:1797.
12. Remi L, Leprêtre S, Arnoulet C, Baseggio L, Campos L, Chatelain B, et al. CLL2007FMP, a phase III randomized multicentric trial of the French Cooperative Group on CLL and WM (FCGCLL/MW) and the "Groupe Ouest-Est D'etudes Des Leucemies Aigues Et Autres Maladies Du Sang" (GOELAMS): immunochemotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) yields a significantly better response than fludarabine (F), cyclophosphamide (C) and MabCampath (Cam) (FCCam) in previously untreated B-chronic lymphocytic leukemia patients as evaluated by a sensitive 6 color flow cytometry MRD. Blood 2010;116:698.
13. Boettcher S, Fischer K, Stilgenbauer S, Busch R, Fingerle-Rowson G, Fink AM, et al. Quantitative MRD assessments predict progression free survival in CLL patients treated with fludarabine and cyclophosphamide with or without rituximab - a prospective analysis in 471 patients from the randomized GCLLSG CLL8 trial. Blood 2008;112:326.
14. Bottcher S, Stilgenbauer S, Busch R, Bruggemann M, Raff T, Pott C, et al. Standardized MRD flow and ASO IGH RQ-PCR for MRD quantification in CLL patients after rituximab-containing immunochemotherapy: a comparative analysis. Leukemia 2009;23(11):2007-17.
15. Cramer P, Fink A, Busch R, Eichhorst B, Wendtner CM, Pflug N, et al. Second-line therapies after treatment with fludarabine, cyclophosphamide, and rituximab (FCR) or fludarabine and cyclophosphamid alone (FC) for chronic lymphocytic leukemia (CLL) within the CLL8-protocol of the German CLL Study Group (GCLLSG). Blood 2011;118:2863.
16. Edelmann J, Holzmann K, Kuhn WMM, Bullinger L, Radtke I, Su X, et al. High-resolution SNP-array profiling of chronic lymphocytic leukemia. Blood 2010;116:50.
17. Eichhorst B, Fischer K, Fink A, Fingerle-Rowson G, Westermann A, Wendtner C-M, et al. Health related quality of life (HRQOL) in patients receiving chemoimmunotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) or fludarabine and cyclophosphamide (FC) for first line therapy with advanced chronic lymphocytic leukemia (CLL). Blood 2009;114(22):3438.
18. Eichhorst BF, Fischer K, Fink AM, Elter T, Wendtner CM, Goede V, et al. Limited clinical relevance of imaging techniques in the follow-up of patients with advanced chronic lymphocytic leukemia: results of a meta-analysis. Blood 2011;117(6):1817-21.
19. Fink A, Busch R, Pflug N, Boettcher S, Winkler D, Buehler A, et al. Prediction of poor outcome in CLL patients treated with FCR (fludarabine, cyclophosphamide, rituximab) in the CLL8 trial of the German CLL Study Group (GCLLSG). Blood 2011;118:977.
20. Fink A, Pflug N, Busch R, Fingerle-Rowson GR, Eichhorst B, Wendtner CM, et al. Serum factors predict therapeutic outcome in patients with chronic lymphocytic leukemia treated in the CLL8 trial of the German CLL Study Group (GCLLSG). Blood 2010;116:918.
21. Hallek M, Fingerle-Rowson G. Phase III trial of combined immunochemotherapy with fludarabine, cyclophosphamide and rituximab (FCR) versus chemotherapy with fludarabine and cyclophosphamide (FC) alone in patients with previously untreated chronic lymphocytic leukaemia CLL-8 / ML17102 Protocol of the German CLL Study Group (GCLLSG). www.dcllsg.de/en/trial/cll8/index.php (only public data used). 2004. (accessed 17 August 2012). Cologne, D.
22. Hallek M, Fingerle-Rowson G, Fink A-M, Busch R, Mayer J, Hensel M, et al. First-line treatment with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) improves overall survival (OS) in previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL): results of a randomized phase III trial on behalf of an International Group of Investigators and the German CLL Study Group. Blood 2009;114(22):535.
23. Hallek M, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, Hensel M, et al. Immunochemotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) versus fludarabine and cyclophosphamide (FC) improves response rates and progression-free survival (PFS) of previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL). Blood 2009;112(11):325.
24. Hallek M, Fischer K, Fingerle-Rowson G, Fink A M, Busch R, Mayer J, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010;376:1164-74.
25. Stilgenbauer S, Zenz T, Winkler D, Buhler A, Busch R, Fingerle-Rowson G, et al. Genomic aberrations, VH mutation status and outcome after fludarabine and cyclophosphamide (FC) or FC plus rituximab (FCR) in the CLL8 trial. Blood 2008;112:781.
26. Zenz T, Busch R, Fink A, Winkler D, Fischer K, Buhler A, et al. Genetics of patients with F-refractory CLL or early relapse after FC or FCR: results from the CLL8 trial of the GCLLSG. Blood 2010;116:2427.
27. Zenz T, Hoth P, Busch R, Helfrich H, Winkler D, Buhler A, et al. TP53 mutations and outcome after fludarabine and cyclophosphamide (FC) or FC plus rituximab (FCR) in the CLL8 trial of the GCLLSG. Blood 2009;114(22):1267.
28. Gribben J, Stephans K, Marshal B. Fludarabine and alemtuzumab versus fludarabine and rituximab in the treatment of relapsed B-cell chronic lymphocytic leukemia: results from a phase II study. Blood 2005;106:343.
29. Hillmen P, Cohen DR, Cocks K, Pettitt A, Sayala HA, Rawstron AC, et al. A randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated chronic lymphocytic leukaemia. British Journal of Haematology 2011;152:570-8.
30. Hillmen P, Pocock C, Cohen D, Cocks K, Sayala HA, Rawstron A, et al. NCRI CLL201 trial: a randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated CLL. Blood 2007;110(11):752.
31. Hillmen P, Pocock C, Cohen D, Gregory W, Cocks K, Rawstron AC, et al. NCRI CLL201 Trial: a randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated CLL. British Journal of Haematology 2008;141(Suppl 1):119.
32. Dornan D, Spleiss O, Yeh RF, Duchateau-Nguyen G, Robak T, Moiseev SI, et al. FC-gamma receptor (FCGR) 2A and 3A polymorphisms do not influence the outcome of relapsed or refractory CLL patients treated with rituximab, fludarabine, and cyclophosphamide (R-FC) or fludarabine, and cyclophosphamide (FC) alone. Blood 2009;114(22):2338.
33. Li J, Zhi J, Wenger MK, Valente N, Visich J. Higher doses of rituximab may be required for patients with CLL as compared to NHL based on population pharmacokinetic (PK) modeling. Blood 2009;114(22):1742.
34. Robak T, Aultman R, Oertel SHK, Carr ESC. Quality-adjusted survival (Q-TWiST) analysis of patients with relapsed or refractory chronic lymphocytic leukaemia treated with rituximab plus fludarabine and cyclophosphamide (R-FC) versus FC alone. Blood 2009;114(22):1368.
35. Robak T, Dmoszynska A, Solal-Celigny P, Warzocha K, Loscertales J, Catalano J, et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. Journal of Clinical Oncology 2010;28(10):1756-65.
36. Robak T, Moiseev SI, Dmoszynska A, Solal-Celigny P, Warzocha K, Loscertales J, et al. Rituximab, fludarabine, and cyclophosphamide (R-FC) prolongs progression free survival in relapsed or refractory chronic lymphocytic leukemia (CLL) compared with FC alone: final results from the international randomized phase III REACH trial. Blood 2008;112:lba-1.
37. Robak T, Szkultecka-Debek M, Aultman R, Carr ES, Kawalec P. Long-term health outcomes and costs associated with the use of rituximab in combination with fludarabine and cyclophosphamide (R-FC) in the treatment of relapsed or refractory chronic lymphocytic leukaemia (CLL) in Poland. Blood 2009;114(22):4528.
38. Wierda W, Jewell RC, Kipps TJ, Dürig J, Griskevicius L, Stilgenbauer S, et al. Correlations between ofatumumab exposure and treatment outcomes for patients with chronic lymphocytic leukemia (CLL) treated with frontline ofatumumab, fludarabine, and cyclophosphamide chemoimmunotherapy (Abstract 1793). Blood. 2011.
39. Wierda WG, Kipps TJ, Durig J, Griskevicius L, Stilgenbauer S, Mayer J, et al. Ofatumumab combined with fludarabine and cyclophosphamide (O-FC) shows high activity in patients with previously untreated chronic lymphocytic leukemia (CLL): results from a randomized, multicenter, international, two-dose, parallel group, phase II trial. Blood 2009;114(22):207.
40. Wierda WG, Kipps TJ, Dürig J, Griskevicius L, Stilgenbauer S, Mayer J. Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia. Blood 2011;117(24):6450-8.
41. Ahmadi T, Schuster SJ. Variations on the fludarabine, cyclophosphamide, and rituximab combination in chronic lymphocytic leukemia therapy: what have we learned?. Journal of Clinical Oncology 2009;27:479-80.
42. Bazargan A, Tam CS. New agents for the treatment of genetically high-risk chronic lymphocytic leukemia. Leukemia & Lymphoma 2010;51:3-4.
43. Byrd JC, O'Brien S, Flinn I, Kipps TJ, Weiss MA, Reid J, et al. Interim results from a phase I study of lumiliximab (IDEC-152, anti-CD23 antibody) therapy for relapsed refractory CLL. Blood 2003;102:74a.
44. Byrd JC, Rai KR, Peterson BL, Appelbaum FR, Morrison VA, Kolitz JE, et al. The addition of rituximab to fludarabine significantly improves progression-free and overall survival in previously untreated chronic lymphocytic leukemia (CLL) patients. Blood 2003;102:73a.
45. Castagna L, Sarina B, Santoro A. Fludarabine plus rituximab for untreated B-cell chronic lymphocytic leukemia. Blood 2003;102:2309-10.
46. Castillo J, Milani C, Mendez-Allwood D. Ofatumumab, a second-generation anti-CD20 monoclonal antibody, for the treatment of lymphoproliferative and autoimmune disorders. Expert Opinion on Investigational Drugs 2009;18:491-500.
47. Decker T, Sandherr M, Goetze K, Oelsner M, Ringshausen I, Peschel C. A pilot trial of the mTOR (mammalian target of rapamycin) inhibitor RAD001 in patients with advanced B-CLL. Annals of Hematology 2009;88:221-7.
48. Drapkin R. Pentostatin and rituximab in the treatment of patients with B-cell malignancies. Oncology 2000;14:25-9.
49. Faderl S, Wierda W, O'Brien S, Ferrajoli A, Lerner S, Keating MJ. Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline CLL <70 Years. Leukemia Research 2010;34:284-8.
50. Han T, Rai KR. Management of chronic lymphocytic leukemia. Hematology - Oncology Clinics of North America 1990;4:431-45.
51. Hillmen P, Skotnicki AB, Robak T, Jaksic B, Dmoszynska A, Wu J, et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. Journal of Clinical Oncology 2007;25:5616-23.
52. Janssens A, Foa R, Keating M, Ouwens M, Tatt I, Carr ESC. Comparative efficacy of first line therapies for chronic lymphocytic leukemia: a systematic review and meta-analyses. Blood 2009;114:3432.
53. Keating MJ, Wierda WG, Tam CS, Lynn A, O'Brien S, Lerner S, et al. Long term outcome following treatment failure of FCR chemoimmunotherapy as initial therapy for chronic lymphocytic leukemia. Drug Discovery 2009;114:2381.
54. Keating MJ, Dritselis A, Yasothan U, Kirkpatrick P. Ofatumumab. Blood 2010;9:101-2.
55. Mulligan SP, Gill DS, Renwick WEP, Sulda ML, Best OG, Kuss BJ, et al. The safety and tolerability of oral fludarabine, (+/-)oral cyclophosphamide and iv rituximab therapy in previously untreated patients with chronic lymphocytic leukaemia (CLL) aged >=65 years - interim analysis from the Australasian Leukaemia and Lymphoma Group (ALLG) and CLL Australian Research Consortium (CLLARC) CLL5 study. Blood 2010;116:699.
56. Negrea OG, Allen SL, Rai KR, Elstrom R, Abassi R, Farber CM, et al. Subcutaneous injections of low doses of humanized anti-CD20 veltuzumab for treatment of indolent B-cell malignancies. Blood 2009;114:3757.
57. Pitini V, Arrigo C, Altavilla G. Dasatinib induces a response in chronic lymphocytic leukemia. Blood 2009;113:498.
58. Quinn JP, Mohamedbhai S, Chipperfield K, Treacy M, D'Sa S, Nathwani AC. Efficacy of rituximab in combination with steroids in refractory chronic lymphocytic leukemia. Leukemia & Lymphoma 2008;49:1995-8.
59. Reynolds C, Di Bella N, Lyons RM, Hyman WJ, Lee GL, Richards DA, et al. Phase III trial of fludarabine, cyclophosphamide, and rituximab vs. pentostatin, cyclophosphamide, and rituximab in B-cell chronic lymphocytic leukemia. Blood 2008;112:327.
60. Rigacci L, Puccini B, Orciuolo E, D'Arco A, Storti S, Gaidano G, et al. Safety and efficacy of bendamustine with or without rituximab for the treatment of heavily pretreated CLL and lymphoma patients. A multicenter retrospective study. Blood 2009;114:1662.
61. Rosen ST. Recent advances and future directions using monoclonal antibodies for B-cell malignancies. Seminars in Oncology 1999;26:1-122.
62. Schweighofer CD, Ritgen M, Eichhorst BF, Busch R, Abenhardt W, Kneba M, et al. Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG). British Journal of Haematology 2009;144:95-8.
63. Tonino SH, van Gelder M, Eldering E, van Oers MH, Kater AP. R-DHAP is effective in fludarabine-refractory chronic lymphocytic leukemia. Leukemia 2010;24:652-4.
64. Alemtuzumab and rituximab for consolidation in CLL (NCT00771602). Ongoing study August 2008.
65. A study to compare subcutaneous versus intravenous MabThera (rituximab) in combination with chemotherapy in patients with CLL (NCT01292603). Ongoing study February 2011.
66. Fludarabine, cyclophosphamide, and rituximab followed by rituximab or observation in treating older patients with previously untreated CLL (NCT00645606). Ongoing study November 2007.
67. Intensified rituximab pre-phase before FluC-R in untreated CLL (NCT01370772). Ongoing study May 2011.
68. Rituximab and alemtuzumab in treating older patients with progressive CLL (NCT01013961). Ongoing study October 2010.
69. Foa R, Alietti A, Guarini A, Ciolli S, Di Raimondo F, Del Poeta G, et al. A phase II study of chlorambucil + rituximab (Clb-R) followed by R maintenance vs observation in elderly patients with previously untreated chronic lymphocytic leukemia (CLL): induction phase results. Haematologica 2011;96:226.
70. Foa R, Ciolli S, Di Raimondo F, Del Poeta G, Lauria F, Forconi F, et al. Rituximab plus chlorambucil as initial treatment for elderly patients with chronic lymphocytic leukemia (CLL): effect of pre-treatment biological characteristics and gene expression patterns on response to treatment. Blood 2011;118:294.
71. Foa R, Ciolli S, Di Raimondo F, Del'Poeta G, Lauria F, Forconi F, et al. A phase II study of chlorambucil plus rituximab followed by maintenance versus observation in elderly patients with previously untreated chronic lymphocytic leukemia: results of the first interim analysis. Blood 2010;116:2462.
72. Mauro FR, Ciolli S, Di Raimondo F, Del Poeta G, Forconi F, Cuneo A, et al. A phase II study of chlorambucil plus rituximab followed by maintenance versus observation in elderly patients with previously untreated chronic lymphocytic leukemia: results of the induction phase. Journal of Clinical Oncology 2011;29:6629.
73. A study comparing RO5072759 (GA101) 1000 mg versus 2000 mg in patients with previously untreated chronic lymphocytic leukaemia (NCT01414205). Ongoing study September 2011.
74. A study of RO5072759 with chlorambucil in patients with previously untreated CLL (NCT01010061). Ongoing study November 2009.
75. Rituximab, fludarabine, and cyclophosphamide or observation alone in treating patients with stage 0, I, or II CLL (NCT00275054). Ongoing study October 2005.
76. Ofatumumab added to FC versus FC in relapsed subjects with CLL (NCT00824265). Ongoing study March 2009.
77. Ofatumumab maintenance treatment versus no further treatment in relapsed CLL responding to induction therapy (PROLONG) (NCT01039376). Ongoing study May 2010.
78. Ofatumumab versus physicians' choice in subjects with bulky fludarabine-refractory chronic lymphocytic leukaemia. Ongoing study April 2011.
79. Rituximab versus observation as maintenance therapy in CLL (NCT01118234). Ongoing study December 2009.
80. A study of maintenance treatment with rituximab in patients with progressive CLL (NCT00718549). Ongoing study July 2009.
81. Ofatumumab + chlorambucil versus chlorambucil monotherapy in previously untreated patients with CLL (NCT00748189). Ongoing study December 2008.
82. Zagoskina P, Demyanova V, Zotina E, Grishina I. Rituximab therapy of chronic lymphocytic leukemia patients in remission. Haematologica 2011;96:225.
83. Badoux X, O'Brien S, Wierda WG, Faderl S, Estrov Z, Yerrow K, et al. Combination of ofatumumab and lenalidomide in patients with relapsed chronic lymphocytic leukemia: initial results of a phase II trial. Blood 2010;116:2464.
84. Binet JL, Auquier A, Dighiero G, Chastang C, Piguet H, Goasguen J, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981;48:198-206.
85. Bosch F, Abrisqueta P, Villamor N, Terol M, Ribera JM, Gonzalez-Barca E, et al. Rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) is a highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia (Abstract 2097). Blood. 2008.
86. Byrd JC, Peterson BL, Morrison VA, Park K, Jacobson R, Hoke E, et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 2003;101(1):6-14.
87. Byrd JC, Rai K, Peterson BL, Appelbaum FR, Morrison VA, Kolitz JE, et al. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 2005;105(1):49-53.
88. Byrd JC, Peterson BL, Rai KR, Hurd D, Hohl R, Perry MC, et al. Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: final report of Cancer and Leukemia Group B study 19901. Leukemia and Lymphoma 2009;50:1589-96.
89. Castro JE, James DF, Sandoval-Sus JD, Jain S, Bole J, Rassenti L, et al. Rituximab in combination with high-dose methylprednisolone for the treatment of chronic lymphocytic leukemia. Leukemia 2009;23:1779-89.
90. Castro JE, Barajas-Gamboa JS, Melo-Cardenas J, Paz RN, Bernal-Corzo C, Ale-Ali A, et al. Ofatumumab and high-dose methylprednisolone is an effective salvage treatment for heavily pretreated, unfit or refractory patients with chronic lymphocytic leukemia: single institution experience. Blood 2010;116:4638.
91. Cheung M, Tey R, Haynes A. Rituximab in chronic lymphocytic leukemia. Program in Evidence-based Care. NGC:007886. 2009. ngc.gov/content.aspx?id=16388&search=Chronic+lymphocytic+leukemia. (accessed 17 August 2012).
92. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. The New England Journal of Medicine 2005;352(8):804-15.
93. Coiffier B, Lepretre S, Pedersen LM, Gadeberg O, Fredriksen H, van Oers MHJ, et al. Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study. Blood 2008;111(3):1094-100.
94. Cramer P, Goede V, Jenke P, Busch R, Hallek M, Eichhorst B. Impact of different chemotherapy regimen in comorbid patients with advanced chronic lymphocytic leukemia: metaanalysis of two phase-III-trials of the German CLL Study Group. Blood 2006;108:2840.
95. Czuczman MS, Gregory SA. The future of CD20 monoclonal antibody therapy in B-cell malignancies. Leukemia and Lymphoma 2010;51:983-94.
96. Deeks JJ, Higgins JPT, Altman DG. Chapter 9: Analysing data and undertaking meta-analyses. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
97. Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. The New England Journal of Medicine 2000;343(26):1910-6.
98. Eichhorst BF, Busch R, Hopfinger G, Pasold R, Hensel M, Steinbrecher C, et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 2006;107(3):885-91.
99. Elter T, Vehreschild JJ, Gribben J, Cornely OA, Engert A, Hallek M. Management of infections in patients with chronic lymphocytic leukemia treated with alemtuzumab. Annals of Hematology 2009;88:121-32.
100. Evens AM, Jovanovic BD, Su YC, Raisch DW, Ganger D, Belknap SM, et al. Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports. Annals of Oncology 2011;22:1170-80.
101. Fischer K, Stilgenbauer S, Schweighofer CD, Busch R, Renschler J, Kiehl M, et al. Bendamustine in combination with rituximab (BR) for patients with relapsed chronic lymphocytic leukemia (CLL): a multicentre phase II trial of the German CLL Study Group (GCLLSG). Blood 2008;112:330.
102. Fischer K, Cramer P, Stilgenbauer S, Busch R, Balleisen L, Kilp J, et al. Bendamustine combined with rituximab (BR) in first-line therapy of advanced CLL: a multicenter phase II trial of the German CLL Study Group (GCLLSG). Blood 2009;114:205.
103. Flinn IW, Neuberg DS, Grever MR, Dewald GW, Bennett JM, Paietta EM, et al. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. Journal of Clinical Oncology 2007;25(7):793-8.
104. Goede V, Fischer K, Busch R, Jaeger U, Dilhuydy MS, Wickham N, et al. Chemoimmunotherapy with chlorambucil and the type II CD20-antibody GA101 in patients with chronic lymphocytic leukemia and comorbidity: results of the run-in phase of the CLL11 (BO21004) trial. Blood 2010;116:1387.
105. Hainsworth JD, Vazquez ER, Spigel DR, Raefsky E, Bearden JD, Saez RA, et al. Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase 2 trial of the Minnie Pearl Cancer Research Network. Cancer 2008;112:1288-95.
106. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008;111(12):5446-56.
107. Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010;376(9747):1164-74.
108. Higgins JPT, Deeks JJ, Altman DG. Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
109. Higgins JPT, Deeks JJ. Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
110. Higgins JPT, Altman DG. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook forSystematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
111. Hillmen P, Skotnicki AB, Robak T, Jaksic B, Dmoszynska A, Wu J, et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. Journal of Clinical Oncology 2007;25(35):5616-23.
112. Hillmen P, Gribben JG, Follows GA, Milligan DW, Sayala HA, Moreton P, et al. An open-label phase II study to investigate the safety and efficacy of rituximab plus chlorambucil in previously untreated patients with CD20-positive B-Cell chronic lymphocytic leukaemia (CLL). Blood 2009;114:3428.
113. Huhn D, von Schilling C, Wilhelm M, Ho AD, Hallek M, Kuse R, et al. Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood 2001;98(5):1326-31.
114. Iannitto E, Morabito F, Mancuso S, Gentile M, Montanini A, Augello A, et al. Bendamustine with or without rituximab in the treatment of relapsed chronic lymphocytic leukaemia: an Italian retrospective study. British Journal of Haematology 2011;153(3):351-7.
115. Jacobs SA, Foon KA. Monoclonal antibody therapy of leukaemias and lymphomas. Expert Opinion on Biological Therapy 2005;5(9):1225-43.
116. Kay NE, Wu W, Kabat B, LaPlant B, Lin TS, Byrd JC, et al. Pentostatin and rituximab therapy for previously untreated patients with B-cell chronic lymphocytic leukemia. Cancer 2010;116:2180-7.
117. Keating MJ, O'Brien S, Albitar M, Lerner S, Plunkett W, Giles F, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. Journal of Clinical Oncology 2005;23(18):4079-88.
118. Lamanna N, Kalaycio M, Maslak P, Jurcic JG, Heaney M, Brentjens R, et al. Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia. Journal of Clinical Oncology 2006;24:1575-81.
119. Lamanna N, Weiss MA. Pentostatin, cyclophosphamide, and rituximab show significant clinical activity in patients with previously untreated chronic lymphocytic leukemia. Current Oncology Reports 2007;9:335-6.
120. Lamanna N, Heaney ML, Brentjens RJ, Jurcic JG, Weiss MA. Pentostatin, cyclophosphamide, rituximab, and mitoxantrone (PCRM): a new highly active regimen for patients with chronic lymphocytic leukemia (CLL) previously treated with PCR or FCR. Blood 2007;110:3115.
121. Lanini S, Molloy AC, Fine PE, Prentice AG, Ippolito G, Kibbler CC. Risk of infection in patients with lymphoma receiving rituximab: systematic review and meta-analysis. BMC Medicine 2011;9:36.
122. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
123. Li B, Shi S, Qian W, Zhao L, Zhang D, Hou S, et al. Development of novel tetravalent anti-CD20 antibodies with potent antitumor activity. Cancer Research 2008;68:2400-8.
124. Li B, Zhao L, Guo H, Wang C, Zhang X, Wu L, et al. Characterization of a rituximab variant with potent antitumor activity against rituximab-resistant B-cell lymphoma. Blood 2009;114:5007-15.
125. Moher D, Liberati A, Tetzlaff J, Altman DG, The PG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Journal of Clinical Epidemiology 2009;62(10):1006-12.
126. Morschhauser F, Cartron G, Lamy T, Milpied NJ, Thieblemont C, Tilly H, et al. Phase I study of RO5072759 (GA101) in relapsed/refractory chronic lymphocytic leukemia. Blood 2009;114:884.
127. National Institute for Health and Clinical Excellence. Rituximab for the first-line treatment of chronic lymphocytic leukaemia. 2009. www.nice.org.uk/nicemedia/live/11907/44906/44906.pdf. (accessed 17 August 2012).
128. National Institute for Health and Clinical Excellence. Ofatumumab for the treatment of chronic lymphocytic leukaemia refractory to fludarabine and alemtuzumab. NGC:008297. 2010. www.nice.org.uk/nicemedia/live/13240/51314/51314.pdf. (accessed 17 August 2012).
129. National Institute for Health and Clinical Excellence. Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia. 2010. www.nice.org.uk/nicemedia/live/13045/49855/49855.pdf. (accessed 17 August 2012).
130. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17(24):2815-34.
131. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood 1975;46(2):219-34.
132. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
133. Robak T, Moiseev SI, Dmoszynska A, Solal-Céligny P, Warzocha K, Loscertales J. Rituximab, fludarabine, and cyclophosphamide (R-FC) prolongs progression free survival in relapsed or refractory Chronic lymphocytic leukemia (CLL) compared with FC alone: final results from the international randomized phase III REACH trial. Blood 2008;112:LBA-1.
134. Robinson KS, Williams ME, van der Jagt RH, Cohen P, Herst JA, Tulpule A, et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. Journal of Clinical Oncology 2008;26(27):4473-9.
135. Schulz H, Klein SK, Rehwald U, Reiser M, Hinke A, Knauf WU, et al. Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia. Blood 2002;100(9):3115-20.
136. Shanafelt TD, Lin T, Geyer SM, Zent CS, Leung N, Kabat B, et al. Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia. Cancer 2007;109:2291-8.
137. Singh JA, Wells GA, Christensen R, Tanjong Ghogomu E, Maxwell L, Macdonald JK, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database of Systematic Reviews 2011, Issue 2. [DOI: 10.1002/14651858.CD008794]
138. Skoetz N, Bauer K, Elter T, Monsef I, Roloff V, Hallek M, et al. Alemtuzumab for patients with chronic lymphocytic leukaemia. Cochrane Database of Systematic Reviews 2012, Issue 2. [DOI: 10.1002/14651858.CD008078]
139. Sterne JAC, Egger M, Moher D. Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
140. Steurer M, Pall G, Richards S, Schwarzer G, Bohlius J, Greil R. Purine antagonists for chronic lymphocytic leukaemia. Cochrane Database of Systematic Reviews 2006, Issue 3. [DOI: 10.1002/14651858.CD004270]
141. Tam CS, O'Brien S, Wierda W, Kantarjian H, Wen S, Do KA, et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 2008;112(4):975-80.
142. Tedder TF, Engel P. CD20: a regulator of cell-cycle progression of B lymphocytes. Immunology Today 1994;15:450-4.
143. Teeling JL, French RR, Cragg MS, van den BJ, Pluyter M, Huang H, et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 2004;104(6):1793-800.
144. Teeling JL, Mackus WJ, Wiegman LJ, van den Brakel JH, Beers SA, French RR, et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. Journal of Immunology 2006;177:362-71.
145. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007;8:16.
146. Wierda W, O'Brien S, Wen S, Faderl S, Garcia-Manero G, Thomas D, et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. Journal of Clinical Oncology 2005;23(18):4070-8.
147. Wierda W, O'Brien S, Faderl S, Ferrajoli A, Wang X, Do KA, et al. A retrospective comparison of three sequential groups of patients with Recurrent/Refractory chronic lymphocytic leukemia treated with fludarabine-based regimens. Cancer 2006;106(2):337-45.
148. Wierda WG, Kipps TJ, Mayer J, Stilgenbauer S, Williams CD, Hellmann A. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. Journal of Clinical Oncology 2010;28(10):1749-55.
149. Wierda WG, Padmanabhan S, Chan GW, Gupta IV, Lisby S, Österborg A. Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase II international study. Blood 2011; Vol. 118:5126-9.